A Study in Sepsis Patients With Renal Failure



Status and phase

Phase 2


Bacterial Infections and Mycoses


Drug: BIAP
Drug: Placebo

Study type


Funder types



AP REN 01-01

Details and patient eligibility


The purpose of this study is to investigate the safety and tolerability of AP in sepsis patients with renal failure and to investigate the effect of AP on inflammatory and clinical parameters in sepsis patients with renal failure.

Full description

RATIONALE FOR THE STUDY A previous clinical study conducted in centers in The Netherlands and Belgium have shown a substantial clinical benefit of AP treatment in patients with sepsis and associated acute renal failure (see Introduction above). The latter results require confirmation in a prospective study, as the current subject of this Protocol. Choice of Drugs The proposed study medication (AP) is identical to the study medication used in the previous clinical study in sepsis patients with single or multiple end-organ failure. Since there is no current proven treatment for these patients, the controls (as in previous studies) is placebo. Choice of patient population The aim is to enroll a maximum of 26 patients positive for sepsis with an APACHE score of ≥20 and ≤28 (determined within 24 hours of entry), and who will be analyzed on an intention to treat (ITT) basis.


36 patients




18 to 80 years old


No Healthy Volunteers

Inclusion criteria

  • Patients between the age of 18 and 80 years.
  • Proven or suspected infection.

Two out of four SIRS criteria of systemic inflammation, existing for less than 24 hours after admission in the intensive care unit, as follows:

  • Core temperature higher then 38 degree Celsius or lower then 36 degree Celsius.
  • Heart rate above 90 beats/min (unless the patient has a medical condition known to increase heart rate or is receiving treatment that would prevent tachycardia).
  • Respiratory rate above 20 breaths/min, a PaCO2 lower then 32mmHg or the use of mechanical ventilation for an acute respiratory process.
  • White-cell count above 12,000/mm3 or below 4,000/mm3 or a differential count showing >10 percent immature neutrophils.

Acute renal failure, defined as

  • Rise in serum creatinine level to ≥150μmol/L within the previous 48 hours, in the absence of primary underlying renal disease OR
  • Minimally a stage 1 Kidney Injury according to AKIN creatinine criteria: Increase in serum creatinine ≥26.2µmol/L (0.3mg/dL) or increase to ≥150% (≥1.5 -fold) from baseline in the previous 48 hours in the absence of primary underlying renal disease and where baseline creatinine is less than 150 µmol/L) OR
  • Minimally a stage 1 Kidney Injury according to AKIN Urine Output criteria: Urine Output of ≤ 0.5mg/kg/h for ≥6h and following adequate fluid resuscitation when applicable, in the absence of underlying primary renal disease and where baseline creatinine is less than 150µmol/L)
  • Written informed consent obtained prior to any study intervention.

Exclusion criteria

  • Pregnant women or nursing mothers and fecund females who are not on effective contraception (chemical: pill; or mechanical: IUD)
  • Patients already on dialysis (RTT) at entry
  • Known HIV (sero-positive) patients
  • Patients receiving immunosuppressant therapy or on chronic high doses of steroids equivalent to prednisone 1mg/Kg/day
  • Patients expected to have rapidly fatal disease within 24 hours
  • Known confirmed gram-positive sepsis
  • Known confirmed fungal sepsis
  • Acute pancreatitis with no established source of infection
  • Patients not expected to survive for 28 days due to other medical conditions such as end-stage neoplasm or other diseases
  • Participation in another investigational study within 90 days prior to start of the study which might interfere with this study
  • Any previous administration of active study medication.
  • Known allergy for dairy (bovine) products including cow milk.
  • Sepsis without renal failure as defined in the Entry Criteria.
  • History of chronic renal failure or history of persistent creatinine level equal or greater than 150umol/L prior to entry for reasons other than the current sepsis condition".

Trial design

Primary purpose




Interventional model

Parallel Assignment


Triple Blind

36 participants in 2 patient groups, including a placebo group

Bovine Intestinal AP
Experimental group
Bovine Intestinal Alkaline Phosphatase (BIAP) Intravenous administration of 10" bolus (67,5U/kg) and 48h continuous infusion (132,5U/kg)
Drug: BIAP
Placebo Comparator group
Placebo Intravenous administration of 10" bolus and 48h continuous infusion
Drug: Placebo

Trial contacts and locations



Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location


© Copyright 2024 Veeva Systems